Good news! Konosay was selected as a national high-tech enterprise

Recently, the Office of the National High-tech Enterprise Identification and Management Leading Group issued the List of the First Batch of High-tech Enterprises Identified and Reported by Qingdao City Accreditation Agency in 2023. Kono Biotech was successfully selected and won the title of national "High-tech Enterprise." This selection is an affirmation of Kono's technological innovation, R & D capability and market competitiveness.

Take the road of independent innovation, unswervingly

Konosai knows that the core technology cannot be bought, and the development depends on its own hard strength after all. The company has always insisted on independent innovation. Its patented super-large pore chromatography separation technology is currently in the leading position in China, and has been verified and recognized by the market. Under the current market environment of serious homogenization of domestic fillers, Konosay has independently developed and produced ultra-large pore chromatography fillers by utilizing the advantages of core technology, breaking the limitations of conventional chromatography fillers and solving the separation and purification problems for customers more efficiently and economically.

For Kono Sai, based on excellent R & D innovation ability and market development ability, under the condition of continuous optimization of technology and products, the self-hematopoietic ability is naturally not bad, and the overall revenue scale will inevitably accelerate to a new level.